A 12-week, phase 2A, randomized, subject and investigator blinded, placebo-controlled trial to evaluate the safety, tolerability and efficacy of CE-326,597 [CE-326597] on glucose control and body weight in overweight adult subjects with type 2 diabetes mellitus.
Phase of Trial: Phase II
Latest Information Update: 12 Nov 2013
At a glance
- Drugs CE 326597 (Primary)
- Indications Obesity; Type 2 diabetes mellitus
- Focus Therapeutic Use
- 31 Aug 2018 Biomarkers information updated
- 16 Mar 2012 Actual end date changed from Nov 2008 to Feb 2009 as reported by European Clinical Trials Database.
- 15 Mar 2012 Additional location (Bulgaria) added as reported by European Clinical Trials Database